Matsumoto Suguru, Nakanishi Rine, Li Dong, Alani Anas, Rezaeian Panteha, Prabhu Sach, Abraham Jeby, Fahmy Michael A, Dailing Christopher, Flores Ferdinand, Hamal Sajad, Broersen Alexander, Kitslaar Pieter H, Budoff Matthew J
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA;
Mercy Medical Center, Merced, CA;
J Nutr. 2016 Feb;146(2):427S-432S. doi: 10.3945/jn.114.202424. Epub 2016 Jan 13.
Although several previous studies have demonstrated that aged garlic extract (AGE) inhibits the progression of coronary artery calcification, its effect on noncalcified plaque (NCP) has been unclear.
This study investigated whether AGE reduces coronary plaque volume measured by cardiac computed tomography angiography (CCTA) in patients with metabolic syndrome (MetS).
Fifty-five patients with MetS (mean ± SD age: 58.7 ± 6.7 y; 71% men) were prospectively assigned to consume 2400 mg AGE/d (27 patients) or placebo (28 patients) orally. Both groups underwent CCTA at baseline and follow-up 354 ± 41 d apart. Coronary plaque volume, including total plaque volume (TPV), dense calcium (DC), NCP, and low-attenuation plaque (LAP), were measured based upon predefined intensity cutoff values. Multivariable linear regression analysis, adjusted for age, gender, number of risk factors, hyperlipidemia medications, history of coronary artery disease, scan interval time, and baseline %TPV, was performed to examine whether AGE affected each plaque change.
The %LAP change was significantly reduced in the AGE group compared with the placebo group (-1.5% ± 2.3% compared with 0.2% ± 2.0%, P = 0.0049). In contrast, no difference was observed in %TPV change (0.3% ± 3.3% compared with 1.6% ± 3.0%, P = 0.13), %NCP change (0.2% ± 3.3% compared with 1.4% ± 2.9%, P = 0.14), and %DC change (0.2% ± 1.4%, compared with 0.2% ± 1.7%, P = 0.99). Multivariable linear regression analysis found a beneficial effect of AGE on %LAP regression (β: -1.61; 95% CI: -2.79, -0.43; P = 0.008).
This study indicates that the %LAP change was significantly greater in the AGE group than in the placebo group. Further studies are needed to evaluate whether AGE has the ability to stabilize vulnerable plaque and decrease adverse cardiovascular events. This trial was registered at clinicaltrials.gov as NCT01534910.
尽管先前的多项研究表明, aged garlic extract (AGE) 可抑制冠状动脉钙化进展,但其对非钙化斑块 (NCP) 的影响尚不清楚。
本研究调查了AGE是否能降低代谢综合征 (MetS) 患者经心脏计算机断层扫描血管造影 (CCTA) 测量的冠状动脉斑块体积。
55例MetS患者(平均±标准差年龄:58.7±6.7岁;71%为男性)被前瞻性地分配为口服2400 mg AGE/d(27例患者)或安慰剂(28例患者)。两组在基线时和间隔354±41 d的随访时均接受CCTA检查。根据预先定义的强度截断值测量冠状动脉斑块体积,包括总斑块体积 (TPV)、致密钙 (DC)、NCP和低衰减斑块 (LAP)。进行多变量线性回归分析,对年龄、性别、危险因素数量、高脂血症药物、冠状动脉疾病史、扫描间隔时间和基线TPV百分比进行校正,以检查AGE是否影响每个斑块的变化。
与安慰剂组相比,AGE组的LAP变化百分比显著降低(分别为-1.5%±2.3%和0.2%±2.0%,P = 0.0049)。相比之下,TPV变化百分比(分别为0.3%±3.3%和1.6%±3.0%,P = 0.13)、NCP变化百分比(分别为0.2%±3.3%和1.4%±2.9%,P = 0.14)和DC变化百分比(分别为0.2%±1.4%和0.2%±1.7%,P = 0.99)未观察到差异。多变量线性回归分析发现AGE对LAP回归有有益影响(β:-1.61;95%CI:-2.79,-0.43;P = 0.008)。
本研究表明,AGE组的LAP变化百分比显著大于安慰剂组。需要进一步研究来评估AGE是否具有稳定易损斑块和减少不良心血管事件的能力。本试验在clinicaltrials.gov注册,注册号为NCT01534910。